The current study is the first indicating that the anti-melanoma role of PDGFR-alpha may be linked to the known anti-melanoma role of CXCL10/IP-10, and suggests PDGFR-alpha and CXCL10/IP-10 as related targets in melanoma therapy, likely via miR-503. This evidence concerns the gene CXCL10 and melanoma.